NGNE vs NNNN: fair value comparison
Neurogene Inc. and Anbio Biotechnology · Updated 2026-10-19
NGNE has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. NNNN has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, NGNE currently ranks higher by quality score.
| NGNE | NNNN | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $23.25 | $3.13 |
| 12-month range | $16.37–$42.84 | $3.13–$41.11 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #254 of 301 Healthcare | #255 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | — |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Mixed | Downtrend |
| 52-week position | The lower-middle quarter | The bottom quarter |
Full single-stock breakdowns: NGNE fair value analysis · NNNN fair value analysis